| |
Now Available On-Demand Navigating the complexities of the rapidly evolving landscape of cell therapy manufacturing poses significant challenges. Access this webinar on-demand todayto learn more about the top challenges cell therapy developers are facing. Explore the need for closed, automated, and flexible manufacturing workflows that are designed to de-risk the process for clinical and commercial success. View now.
|
|
| By Eric Sagonowsky Two months after closing its multibillion-dollar acquisition of Mirati Therapeutics, Bristol Myers Squibb is bidding adieu to more than 250 workers at the biotech's headquarters in California. |
|
|
|
By Gabrielle Masson After GSK’s $2 billion buyout of Canada-based Bellus Health last summer, an undisclosed number of the biotech’s team members are out of a job. |
By James Waldron Regeneron may have gotten ahead of itself with the early filing of bispecific antibody odronextamab to regulators. In a move that might not surprise keen FDA watchers, the agency has issued two complete response letters over the timelines of ongoing phase 3 confirmatory trials for the drug. |
By Angus Liu The CEOs of AstraZeneca, Bayer, Bristol Myers Squibb, GSK, Novartis, Pfizer and Takeda came together in Beijing to show the companies’ continued interest in China and to offer their advice for the country’s healthcare industry. |
|
Wednesday, April 17, 2024 | 12pm ET / 9am PT Register now to create effective pharma marketing campaigns by targeting both HCPs and consumers. Discover strategies for linking patient-physician interactions and utilizing social determinants of health data. Gain insights on identifying relevant HCPs, creating consumer audiences, and tailoring messages for maximum impact.
|
|
By Ben Adams It’s March, so it’s time for some #FierceMadness. Last year, we channeled the NCAA tournament for the best pharma ad campaigns, but this year we’re looking for the best of the best in drug names. |
By Annalee Armstrong,Max Bayer,Gabrielle Masson,James Waldron What's the best biotech name? It's time to vote in the Fierce Madness #biotechbracket. |
By Kevin Dunleavy With a positive recommendation from Europe’s Committee for Medicinal Products for Human Use (CHMP), Novo has come a step closer to bringing its revolutionary Awiqli (once-weekly basal insulin icodec) to the market. It was one of several opinions handed down by the CHMP. |
By Max Bayer Moderna's next-gen COVID vaccine beat its approved counterpart in phase 3, boasting a stronger immune response. The new data is critical to Moderna's combo ambitions. |
By Conor Hale Researchers at the University of Washington's Baker Lab have shown that a generative AI program can help draw up atomically accurate antibodies from scratch—including those capable of binding to the proteins found in COVID-19, RSV and influenza. |
By Angus Liu As geopolitical tensions threaten to disrupt pharmaceutical supply chains, AstraZeneca is making plans to manufacture drugs for the U.S. and China markets independently from one another. |
By Helen Floersh A common microbe that migrates from the mouth to the gut may be responsible for driving the progression of colorectal cancer, new findings from the Fred Hutchinson Cancer Center suggest. |
By Andrea Park Call it a silver lining: In addition to stopping the increasingly ludicrous theories for her absence from the public eye, Kate Middleton’s reveal last week that she’s fighting cancer may also be boosting awareness of the early signs and symptoms of the disease. |
Fierce podcastsDon’t miss an episode |
| | This week on “The Top Line,” we explore the European biotech investment landscape. Fierce Biotech’s James Waldron sits down with Maina Bhaman, a Partner at Sofinnova Capital Strategy, who provides insights into how investors are approaching the European biotech sector. |
|
|---|
|
|
| WhitepaperExplore the nuanced approaches necessary for successful pediatric drug development. Sponsored by: PPD |
| Whitepaper This paper assesses the current state of the broad CNS market, reviewing key expectations for 2024. It addresses Alzheimer’s disease, biomarkers, and advances in psychiatry in detail. It also provides a high-level look at the pain market and the evolving regulatory environment. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperExplore the complex considerations of vaccine development for influenza and COVID-19, including the challenges posed by viral evolution and the importance of ongoing research in this paper by vaccine expert, Dr. Lisa Kierstead. Sponsored by: PPD®️ Laboratory Services |
| WhitepaperAmidst rapid change, it is crucial for specialty distributors to maintain a balance of service and quality for manufacturers, ensuring neither is sacrificed. Explore why this balance is paramount for success in the evolving landscape of pharma. Sponsored by: BioCare |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
